Immunotherapy targeting drug-tolerant Mycobacterium tuberculosis persisters accelerates tuberculosis cure in preclinical models (Karanika et al, 2026)

Congratulations to Dr. Styliani Karanika, who is a JHU TRAC ESI, Mentee, and Developmental Awardee on this publication in the Journal of Clinical Investigation!  The open-access full article is available here and the full citation is listed below.

null

 

Karanika S, Wang T, Yilma A, Ruelas Castillo J, Gordy JT, Bailey H, Quijada D, Fessler K, Tasneen R, Rouse Salcido EM, Shamma F, Harris HT, Chen F, Bates RE, Ton H, Meza J, Li Y, Taylor AD, Zheng JJ, Zhang J, Karantanos T, Maxwell AR, Nuermberger EL, Peske JD, Markham RB, Karakousis PC. Immunotherapy targeting drug-tolerant Mycobacterium tuberculosis persisters accelerates tuberculosis cure in preclinical models. J Clin Invest. 2026 Feb 3:e196648. doi: 10.1172/JCI196648. Epub ahead of print. PMID: 41632540.

 

Linezolid does not improve bactericidal activity of rifampin-containing first-line regimens in animal models of TB meningitis

Tucker EW, Ruiz-Bedoya CA, Mota F, Erice C, Kim J, de Jesus P, Jahdav R, Bahr M, Flavahan K, Chen X, Peloquin CA, Freundlich JS, Jain SK. Linezolid does not improve bactericidal activity of rifampin-containing first-line regimens in animal models of TB meningitis. Int J Antimicrob Agents. 2024 Jan;63(1):107048. doi: 10.1016/j.ijantimicag.2023.107048. Epub 2023 Dec 5. PMID: 38061419; PMCID: PMC10841818.

Differentially culturable tubercle bacteria as a measure of tuberculosis treatment response

Peters JS, McIvor A, Papadopoulos AO, Masangana T, Gordhan BG, Waja Z, Otwombe K, Letutu M, Kamariza M, Sterling TR, Bertozzi CR, Martinson NA, Kana BD. Differentially culturable tubercle bacteria as a measure of tuberculosis treatment response. Front Cell Infect Microbiol. 2023 Jan 12;12:1064148. doi: 10.3389/fcimb.2022.1064148. PMID: 36710965; PMCID: PMC9877613.